Last update 04 Nov 2024

Everstar Medicines (Shanghai) Limited

Private Company | Subsidiary Company|
2018|
Shanghai Shi, China

Overview

Tags

Urogenital Diseases
Immune System Diseases
Digestive System Disorders
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases2
Immune System Diseases2
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug3
Top 5 TargetCount
PGI2 receptor(Prostanoid IP receptor)1
S1PR1 x S1PR4 x S1PR51
GR(Glucocorticoid receptor)1

Related

3
Drugs associated with Everstar Medicines (Shanghai) Limited
Etrasimod Arginine
Target
S1PR1 x S1PR4 x S1PR5
Mechanism
EDG6 agonists [+2]
Active Org.
Pfizer Inc.Pfizer Inc. [+7]
Originator Org.
Arena Pharmaceuticals, Inc.Arena Pharmaceuticals, Inc.
Active Indication
Ulcerative colitis, active moderate [+7]
Inactive Indication
Dermatitis, Atopic [+5]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date12 Oct 2023
Budesonide
Target
GR
Mechanism
GR agonists
Active Org.
Calliditas Therapeutics ABCalliditas Therapeutics AB [+28]
Originator Org.
AstraZeneca Pharmaceuticals Co. Ltd.AstraZeneca Pharmaceuticals Co. Ltd.
Active Indication
Glomerulonephritis, IGA [+9]
Inactive Indication
Acute Graft Versus Host Disease [+19]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date14 Feb 1994
Ralinepag
Target
PGI2 receptor
Mechanism
PGI2 receptor agonists
Active Org.
United Therapeutics Corp.United Therapeutics Corp. [+4]
Originator Org.
Arena Pharmaceuticals, Inc.Arena Pharmaceuticals, Inc.
Active Indication
Pulmonary Arterial Hypertension [+3]
Inactive Indication-
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
8
Clinical Trials associated with Everstar Medicines (Shanghai) Limited
CTR20201798 / CompletedPhase 1
一项I期、单中心、开放研究评估Nefecon单次给药在中国健康志愿者中的药代动力学特征及安全性
[Translation] A Phase I, single-center, open-label study to evaluate the pharmacokinetic characteristics and safety of a single dose of Nefecon in healthy Chinese volunteers
CTR20200001 / RecruitingPhase 1
一项评价Ralinepag缓释片在健康中国受试者中的药代动力学、安全性及耐受性的开放标签、非随机的单剂量递增1期研究
[Translation] An open-label, non-randomized, single-ascending dose phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of Ralinepag extended-release tablets in healthy Chinese subjects
CTR20200301 / CompletedPhase 3
随机、双盲、安慰剂对照研究评估Nefecon在具有进展为终末期肾病风险的原发性IgA肾病患者中的疗效和安全性
[Translation] A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Nefecon in patients with primary IgA nephropathy at risk for progression to end-stage renal disease
100 Clinical Results associated with Everstar Medicines (Shanghai) Limited
Login to view more data
0 Patents (Medical) associated with Everstar Medicines (Shanghai) Limited
Login to view more data
100 Deals associated with Everstar Medicines (Shanghai) Limited
Login to view more data
100 Translational Medicine associated with Everstar Medicines (Shanghai) Limited
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
2
Phase 3
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free